RxDoctor Payments Data

Zhi Hao Huang, OD

Optometrist · Zephyrhills, FLNPI 1164945432

Payments from drug & device makers

$4,335in general payments, 2019–2025

Across 150 payments — averaging $28.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$1K
  • Sun Pharmaceutical Industries Inc.$709
  • AbbVie$612
  • Alimera Sciences, Inc.$367
  • Amgen$261
  • Kala Pharmaceuticals, Inc.$219
  • plus $954 from 17 others

What the payments were for

  • Food & beverage$4,335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,335 in reported general payments places this provider in the 85th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$146,069
Medicare patients
806
Services billed
1,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$18,837
ProlensaBromfenac Sodium49$17,120
CombiganBrimonidine Tartrate/Timolol17$4,189
LumiganBimatoprost13$3,237
SimbrinzaBrinzolamide/Brimonidine Tart12$2,300
Timolol Maleate245$1,942
Brimonidine Tartrate100$1,842
Prednisolone Acetate48$1,409
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,357
Azithromycin172$1,329
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat73$1,084
Latanoprost101$725
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$398
Dorzolamide Hcl26$363
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$612$26,26351 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$53$17,12049 claims
AlconSimbrinza$65$2,30012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →